164 related articles for article (PubMed ID: 17382517)
21. The TC21 oncoprotein interacts with the Ral guanosine nucleotide dissociation factor.
López-Barahona M; Bustelo XR; Barbacid M
Oncogene; 1996 Feb; 12(3):463-70. PubMed ID: 8637701
[TBL] [Abstract][Full Text] [Related]
22. rsc: a novel oncogene with structural and functional homology with the gene family of exchange factors for Ral.
D'Adamo DR; Novick S; Kahn JM; Leonardi P; Pellicer A
Oncogene; 1997 Mar; 14(11):1295-305. PubMed ID: 9178890
[TBL] [Abstract][Full Text] [Related]
23. Double-mutant analysis of the interaction of Ras with the Ras-binding domain of RGL.
Shirouzu M; Hashimoto K; Kikuchi A; Yokoyama S
Biochemistry; 1999 Apr; 38(16):5103-10. PubMed ID: 10213614
[TBL] [Abstract][Full Text] [Related]
24. Sequential activation of Rap1 and Rac1 small G proteins by PDGF locally at leading edges of NIH3T3 cells.
Takahashi M; Rikitake Y; Nagamatsu Y; Hara T; Ikeda W; Hirata K; Takai Y
Genes Cells; 2008 Jun; 13(6):549-69. PubMed ID: 18422604
[TBL] [Abstract][Full Text] [Related]
25. Nitric oxide activates Rap1 and Ral in a Ras-independent manner.
Mittar D; Sehajpal PK; Lander HM
Biochem Biophys Res Commun; 2004 Sep; 322(1):203-9. PubMed ID: 15313192
[TBL] [Abstract][Full Text] [Related]
26. Human cDNAs rap1 and rap2 homologous to the Drosophila gene Dras3 encode proteins closely related to ras in the 'effector' region.
Pizon V; Chardin P; Lerosey I; Olofsson B; Tavitian A
Oncogene; 1988 Aug; 3(2):201-4. PubMed ID: 3045729
[TBL] [Abstract][Full Text] [Related]
27. Colocalization of Ras and Ral on the membrane is required for Ras-dependent Ral activation through Ral GDP dissociation stimulator.
Kishida S; Koyama S; Matsubara K; Kishida M; Matsuura Y; Kikuchi A
Oncogene; 1997 Dec; 15(24):2899-907. PubMed ID: 9416833
[TBL] [Abstract][Full Text] [Related]
28. Identification of the guanine nucleotide dissociation stimulator for Ral as a putative effector molecule of R-ras, H-ras, K-ras, and Rap.
Spaargaren M; Bischoff JR
Proc Natl Acad Sci U S A; 1994 Dec; 91(26):12609-13. PubMed ID: 7809086
[TBL] [Abstract][Full Text] [Related]
29. Identification of a novel RalGDS-related protein as a candidate effector for Ras and Rap1.
Peterson SN; Trabalzini L; Brtva TR; Fischer T; Altschuler DL; Martelli P; Lapetina EG; Der CJ; White GC
J Biol Chem; 1996 Nov; 271(47):29903-8. PubMed ID: 8939933
[TBL] [Abstract][Full Text] [Related]
30. The activation of RalGDS can be achieved independently of its Ras binding domain. Implications of an activation mechanism in Ras effector specificity and signal distribution.
Linnemann T; Kiel C; Herter P; Herrmann C
J Biol Chem; 2002 Mar; 277(10):7831-7. PubMed ID: 11748241
[TBL] [Abstract][Full Text] [Related]
31. [Regulation of a small GTPase Rap2].
Ohba Y
Hokkaido Igaku Zasshi; 2001 Jan; 76(1):13-20. PubMed ID: 11235208
[TBL] [Abstract][Full Text] [Related]
32. RasGEF1A and RasGEF1B are guanine nucleotide exchange factors that discriminate between Rap GTP-binding proteins and mediate Rap2-specific nucleotide exchange.
Yaman E; Gasper R; Koerner C; Wittinghofer A; Tazebay UH
FEBS J; 2009 Aug; 276(16):4607-16. PubMed ID: 19645719
[TBL] [Abstract][Full Text] [Related]
33. Pressure-induced local unfolding of the Ras binding domain of RalGDS.
Inoue K; Yamada H; Akasaka K; Herrmann C; Kremer W; Maurer T; Döker R; Kalbitzer HR
Nat Struct Biol; 2000 Jul; 7(7):547-50. PubMed ID: 10876238
[TBL] [Abstract][Full Text] [Related]
34. Rap1 mutants with increased affinity for the guanine-nucleotide exchange factor C3G.
Shi S; Noda M; Kitayama H
Oncogene; 2004 Nov; 23(54):8711-9. PubMed ID: 15480424
[TBL] [Abstract][Full Text] [Related]
35. A detailed thermodynamic analysis of ras/effector complex interfaces.
Kiel C; Serrano L; Herrmann C
J Mol Biol; 2004 Jul; 340(5):1039-58. PubMed ID: 15236966
[TBL] [Abstract][Full Text] [Related]
36. [Are rap genes anti-oncogenes?].
de Gunzburg J
Bull Cancer; 1993 Aug; 80(8):723-7. PubMed ID: 8204955
[TBL] [Abstract][Full Text] [Related]
37. C3G-mediated suppression of oncogene-induced focus formation in fibroblasts involves inhibition of ERK activation, cyclin A expression and alterations of anchorage-independent growth.
Guerrero C; Martín-Encabo S; Fernández-Medarde A; Santos E
Oncogene; 2004 Jun; 23(28):4885-93. PubMed ID: 15077165
[TBL] [Abstract][Full Text] [Related]
38. High-resolution structural analysis of mammalian profilin 2a complex formation with two physiological ligands: the formin homology 1 domain of mDia1 and the proline-rich domain of VASP.
Kursula P; Kursula I; Massimi M; Song YH; Downer J; Stanley WA; Witke W; Wilmanns M
J Mol Biol; 2008 Jan; 375(1):270-90. PubMed ID: 18001770
[TBL] [Abstract][Full Text] [Related]
39. Biochemical and biological analyses of Rgr RalGEF oncogene.
Martello LA; Pellicer A
Methods Enzymol; 2006; 407():115-28. PubMed ID: 16757319
[TBL] [Abstract][Full Text] [Related]
40. PARG1, a protein-tyrosine phosphatase-associated RhoGAP, as a putative Rap2 effector.
Myagmar BE; Umikawa M; Asato T; Taira K; Oshiro M; Hino A; Takei K; Uezato H; Kariya K
Biochem Biophys Res Commun; 2005 Apr; 329(3):1046-52. PubMed ID: 15752761
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
